455 Mission Bay Boulevard South, San Francisco, CA 94158 info@acterisinc.com +1 888 774 7472



Multiplex edited 2

First published in Nature in 2014, Acteris’ founders discovered key insights in predicting cancer immunotherapy activity. By combining quantitative proteomics with specific immune cell density and location, the investigators predicted treatment outcome in metastatic melanomas in patients receiving therapies that block the PD-1/PD-L1 axis. Specifically, the release of the PD-1 immune checkpoint results in clinically relevant anti-tumour activity when there is a greater density of pre-existing tumor-antigen-restricted CD8+ T cells that are negatively regulated by PD-1/PD-L1 interactions.

Acteris researchers have enhanced the operationalization of this process from a manual process to an automated pathology system, enabling higher and more efficient throughput for patient and clinical trial analysis.

Paul C. Tumeh, MD, Assistant Professor of Dermatology describes Acteris’ technology as extending the current understanding of cancer immunotherapeutic agents and providing direction to develop new generations of compounds.